With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Sanofi's latest digital health move will see it collaborating with Happify Health on a digital therapeutic for patients with multiple sclerosis, a therapeutic area it knows well.

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?

Emerging Company Profile: CHF16m for Swiss firm that engineers liposomes to capture toxins and protect the organs of patients with acute liver failure.

Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.

Aimmune’s oral immunotherapy seems destined to come to market with a strict REMS, though analysts do not expect this will impact adoption. DBV is awaiting word on whether the FDA will review its second attempt at a BLA submission for Viaskin Peanut.

Novartis’s breast cancer therapy Piqray is endorsed by an expert panel for marketing in India and the Swiss company has emphasized its commitment to value-based pricing for the product.

Filing stays litigation but state attorneys general will be battling company's settlement proposal in US bankruptcy court. Details emerge on Purdue finances, rebate expenditures and litigation costs.

The company has discontinued a Phase II trial for BG00011, which was acquired in its 2012 Stromedix purchase, due to safety issues.

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.